Latest news with #RandallLipps
Business Wire
06-05-2025
- Business
- Business Wire
Omnicell Announces First Quarter 2025 Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ('Omnicell,' 'we,' 'our,' 'us,' 'management,' or the 'Company'), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. 'We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous Pharmacy including medication management solutions across the continuum of care,' stated Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. 'While uncertainty surrounding the potential impact of tariffs has compelled us to update our full-year outlook, our focus on driving annual recurring revenue services and recurring revenue is expected to serve us well as we implement strategies that are designed to mitigate the potential impact of tariffs on our supply chain. Importantly, our balance sheet remains strong, with solid free cash flow, which should help us remain nimble and capable of navigating the current macroeconomic environment while continuing to offer market-leading innovation and execution that our customers have come to expect.' Financial Results Total revenues for the first quarter of 2025 were $270 million, up $24 million, or 10%, from the first quarter of 2024. The year-over-year increase in total revenues is primarily due to the increase in revenues from our XT Amplify program, as well as continued growth in our SaaS and Expert Services, including an increase in revenues from our Specialty Pharmacy Services offering. Total GAAP net loss for the first quarter of 2025 was $7 million, or $0.15 per diluted share. This compares to GAAP net loss of $16 million, or $0.34 per diluted share, for the first quarter of 2024. Total non-GAAP net income for the first quarter of 2025 was $12 million, or $0.26 per diluted share. This compares to non-GAAP net income of $1 million, or $0.03 per diluted share, for the first quarter of 2024. Total non-GAAP EBITDA for the first quarter of 2025 was $24 million. This compares to non-GAAP EBITDA of $11 million for the first quarter of 2024. Balance Sheet As of March 31, 2025, Omnicell's balance sheet reflected cash and cash equivalents of $387 million, total debt (net of unamortized debt issuance costs) of $341 million, and total assets of $2.2 billion. Cash flows provided by operating activities in the first quarter of 2025 totaled $26 million. This compares to cash flows provided by operating activities totaling $50 million in the first quarter of 2024. As of March 31, 2025, the Company had $350 million of availability under its revolving credit facility with no outstanding balance. Corporate Highlights Omnicell will celebrate the grand opening of the Company's Austin Innovation Lab on Wednesday, May 14, 2025. This new facility will serve as a hub for Omnicell engineers and product development teams to develop and test new solutions that are focused on solving customer pain points as part of the Company's evolving portfolio of medication and supply management solutions. Omnicell's Bangalore location continues to evolve into a strategic talent hub, and, in April 2025, the Company opened a new office for its India-based software development center where teams are focused on accelerating Omnicell's cloud strategy and its suite of cloud-based hardware, software and technology-enabled services. 2025 Guidance The table below summarizes Omnicell's second quarter and updated full year 2025 guidance. Given potential higher supply chain costs related to the fluid tariff environment, we have reduced our full year 2025 guidance ranges for non-GAAP EBITDA and non-GAAP earnings per share. The Company does not provide guidance for GAAP net income or GAAP earnings per share, nor a reconciliation of any forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis, because it is unable to predict certain items contained in the GAAP measures without unreasonable efforts. These forward-looking non-GAAP financial measures do not include certain items, which may be significant, including, but not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes. Omnicell Conference Call Information Omnicell will hold a conference call today, Tuesday, May 6, 2025, at 8:30 a.m. ET to discuss first quarter 2025 financial results. The conference call can be monitored by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 7437144. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at About Omnicell Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics, all optimized by expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit From time to time, Omnicell may use the Company's investor relations website and other online social media channels, including its LinkedIn page and Facebook page to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure ('Reg FD'). OMNICELL, the Omnicell logo, and ENLIVENHEALTH are registered trademarks of Omnicell, Inc. or one of its subsidiaries. This press release may also include the trademarks and service marks of other companies. Such trademarks and service marks are the marks of their respective owners. Forward-Looking Statements To the extent any statements contained in this press release deal with information that is not historical, these statements are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words 'expect,' 'intend,' 'may,' 'will,' 'should,' 'would,' 'could,' 'plan,' 'potential,' 'anticipate,' 'believe,' 'forecast,' 'guidance,' 'outlook,' 'goals,' 'target,' 'estimate,' 'seek,' 'predict,' 'project,' and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell's control. Such statements include, but are not limited to, Omnicell's projected product bookings, revenues, including product, service, technical services and SaaS and Expert Services revenues, annual recurring revenue, non-GAAP EBITDA, and non-GAAP earnings per share; expectations regarding our products and services and developing new or enhancing existing products and solutions and the related objectives and expected benefits (and any implied financial impact); customers' embrace of the industry-defined vision of the Autonomous Pharmacy; our ability to drive recurring revenue and navigate the current macroeconomic environment; the impact of, or ability to mitigate the impact of, tariffs; and statements about Omnicell's strategy, plans, objectives, promise and purpose, vision, goals, opportunities, and market or Company outlook. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell's ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) delays in installations of our medication management solutions or our more complex medication packaging systems, (v) our international operations may subject us to additional risks, including from the impact of tariffs, (vi) risks related to Omnicell's investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (vii) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (viii) Omnicell's ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (x) changes to the 340B Program, (xi) risks related to the incorporation of artificial intelligence technologies into our products, services and processes or our vendors offerings, (xii) Omnicell's substantial debt, which could impair its financial flexibility and access to capital, (xiii) covenants in our credit agreement could restrict our business and operations, (xiv) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (xv) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same; (xvi) any disruption in Omnicell's information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xvii) risks associated with operating in foreign countries, (xviii) Omnicell's ability to recruit and retain skilled and motivated personnel, (xix) Omnicell's ability to protect its intellectual property, (xx) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xxi) Omnicell's dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, (xxii) fluctuations in quarterly and annual operating results may make our future operating results difficult to predict, (xxiii) failing to meet (or significantly exceeding) our publicly announced financial guidance, and (xxiv) other risks and uncertainties further described in the 'Risk Factors' section of Omnicell's most recent Annual Report on Form 10-K, as well as in Omnicell's other reports filed with or furnished to the United States Securities and Exchange Commission ('SEC'), available at Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law. Use of Non-GAAP Financial Information This press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ('GAAP'). Management evaluates and makes operating decisions using various performance measures. In addition to Omnicell's GAAP results, we also consider non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income (loss) from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP diluted shares, non-GAAP EBITDA, non-GAAP EBITDA margin, and non-GAAP free cash flow. These non-GAAP results and metrics should not be considered as an alternative to revenues, gross profit, operating expenses, income from operations, net income, net income per diluted share, diluted shares, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results and metrics because management considers them to be important supplemental measures of Omnicell's performance and refers to such measures when analyzing Omnicell's strategy and operations. Our non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income (loss) from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin are exclusive of certain items to facilitate management's review of the comparability of Omnicell's core operating results on a period-to-period basis because such items are not related to Omnicell's ongoing core operating results as viewed by management. We define our 'core operating results' as those revenues recorded in a particular period and the expenses incurred within such period that directly drive operating income in such period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we believe we should invest in research and development, fund infrastructure growth, and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results: non-GAAP gross profit and non-GAAP gross margin exclude from their GAAP equivalents items a), b) and e) below; non-GAAP operating expenses excludes from its GAAP equivalents items a), b), c), e), f), g), and h) below; non-GAAP income (loss) from operations and non-GAAP operating margin exclude from their GAAP equivalents items a), b), c), e), f), g), and h) below; and non-GAAP net income and non-GAAP net income per diluted share exclude from their GAAP equivalents items a) through h) below. Non-GAAP EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Non-GAAP EBITDA and non-GAAP EBITDA margin exclude from their GAAP equivalents items a), c), d), e), f), g), h) below: a) Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Omnicell. b) Amortization of acquired intangible assets. We excluded from our non-GAAP results the intangible assets amortization expense resulting from our past acquisitions. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results. c) Acquisition-related expenses. We excluded from our non-GAAP results the expenses related to recent acquisitions, including amortization of representations and warranties insurance. These expenses are unrelated to our ongoing operations, vary in size and frequency, and are subject to significant fluctuations from period to period due to varying levels of acquisition activity. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. d) Amortization of debt issuance costs. Debt issuance costs represent costs associated with the issuance of revolving credit facilities and convertible senior notes. The costs include underwriting fees, original issue discount, ticking fees, and legal fees. These non-cash expenses are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results. e) RDS restructuring. We excluded from our non-GAAP results the nonrecurring restructuring charges related to the wind down of the Company's Medimat Robotic Dispensing System ('RDS') product line. For the period ended March 31, 2024, those charges consisted primarily of severance and other related expenses. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. f) Executives transition costs. We excluded from our non-GAAP results the transition costs associated with the departure of a certain executive officer, primarily consisting of severance expenses. These expenses are unrelated to our ongoing operations and we do not expect them to occur in the ordinary course of business. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. g) Legal and regulatory expenses. We excluded from our non-GAAP results certain non-recurring legal and regulatory expenses, representing potential settlement amounts, related to certain claims of non-compliance with our government contracts that are outside of the ordinary course of our business. We believe that excluding these amounts provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. h) Management severance costs. We excluded from our non-GAAP results the severance expense of certain senior management associated with the restructuring of our senior leadership team. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. Expand Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell's control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items. We believe that the presentation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin is warranted for several reasons: a) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell's financial performance by excluding the impact of items which may obscure trends in the core operating results of the business. b) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors' ability to compare our performance across financial reporting periods. c) These non-GAAP financial measures are employed by management in its own evaluation of performance and are utilized in financial and operational decision-making processes, such as budget planning and forecasting. d) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which also use non-GAAP financial measures to supplement their GAAP results (although these companies may calculate non-GAAP financial measures differently than Omnicell does), thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance. Expand Set forth below are additional reasons why share-based compensation expense is excluded from our non-GAAP financial measures: i) While share-based compensation calculated in accordance with Accounting Standards Codification ('ASC') 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of share-based compensation expense to assist management and investors in evaluating our core operating results. ii) We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation under ASC 718 are dependent upon the trading price of Omnicell's common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties, the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results. Expand Non-GAAP diluted shares is defined as our GAAP diluted shares, excluding the impact of dilutive convertible senior notes for which the Company is economically hedged through its anti-dilutive convertible note hedge transaction. Additionally, in a period of net loss, GAAP diluted shares are further adjusted for certain shares whose effect would be dilutive in a period of net income. We believe non-GAAP diluted shares is a useful non-GAAP metric because it provides insight into the offsetting economic effect of the hedge transaction against potential conversion of the convertible senior notes. Non-GAAP free cash flow is defined as net cash provided by operating activities less cash used for software development for external use and purchases of property and equipment. We believe free cash flow is important to enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review and understanding of our overall financial, operational, and economic performance, because free cash flow takes into account certain capital expenditures and cash used for software development necessary to operate our business. As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell's GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are: a) Omnicell's equity incentive plans and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell's GAAP results for the foreseeable future under ASC 718. b) Other companies, including companies in Omnicell's industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure. c) A limitation of the utility of free cash flow as a measure of financial performance is that it does not represent the total increase or decrease in Omnicell's cash balance for the period. Expand A detailed reconciliation between Omnicell's non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Omnicell's other reports filed with or furnished to the SEC. Omnicell, Inc. Condensed Consolidated Balance Sheets (Unaudited, in thousands) March 31, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 386,826 $ 369,201 Accounts receivable and unbilled receivables, net 251,597 256,398 Inventories 91,142 88,659 Prepaid expenses 26,751 25,942 Other current assets 83,351 75,293 Total current assets 839,667 815,493 Property and equipment, net 115,786 112,692 Long-term investment in sales-type leases, net 52,534 52,744 Operating lease right-of-use assets 29,294 25,607 Goodwill 735,956 734,727 Intangible assets, net 182,552 188,266 Long-term deferred tax assets 61,362 57,469 Prepaid commissions 57,758 54,656 Other long-term assets 76,561 79,306 Total assets $ 2,151,470 $ 2,120,960 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 53,271 $ 51,782 Accrued compensation 46,077 60,307 Accrued liabilities 173,627 167,895 Deferred revenues 159,995 141,370 Convertible senior notes, net 174,562 174,324 Total current liabilities 607,532 595,678 Long-term deferred revenues 78,370 76,123 Long-term deferred tax liabilities 1,166 1,108 Long-term operating lease liabilities 33,020 31,123 Other long-term liabilities 7,582 7,218 Convertible senior notes, net 166,700 166,397 Total liabilities 894,370 877,647 Total stockholders' equity 1,257,100 1,243,313 Total liabilities and stockholders' equity $ 2,151,470 $ 2,120,960 Expand Omnicell, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited, in thousands) Three Months Ended March 31, 2025 2024 Operating Activities Net loss $ (7,023 ) $ (15,676 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization 19,995 21,253 Loss on disposal of assets 111 39 Share-based compensation expense 10,786 8,641 Deferred income taxes (3,835 ) (4,609 ) Amortization of operating lease right-of-use assets 1,846 1,930 Amortization of debt issuance costs 735 971 Changes in operating assets and liabilities: Accounts receivable and unbilled receivables 5,545 3,393 Inventories (2,483 ) 6,302 Prepaid expenses (809 ) (619 ) Other current assets (3,401 ) 928 Investment in sales-type leases 84 (1,125 ) Prepaid commissions (3,102 ) 2,223 Other long-term assets 1,650 836 Accounts payable 931 (1,443 ) Accrued compensation (14,230 ) (10,278 ) Accrued liabilities 1,380 5,063 Deferred revenues 20,184 34,121 Operating lease liabilities (2,804 ) (2,778 ) Other long-term liabilities 364 781 Net cash provided by operating activities 25,924 49,953 Investing Activities External-use software development costs (4,567 ) (3,383 ) Purchases of property and equipment (11,172 ) (8,957 ) Net cash used in investing activities (15,739 ) (12,340 ) Financing Activities Proceeds from issuances under stock-based compensation plans 8,266 8,042 Employees' taxes paid related to restricted stock units (2,391 ) (705 ) Change in customer funds, net (1,837 ) 4,589 Net cash provided by financing activities 4,038 11,926 Effect of exchange rate changes on cash and cash equivalents 1,565 (556 ) Net increase in cash, cash equivalents, and restricted cash 15,788 48,983 Cash, cash equivalents, and restricted cash at beginning of period 398,614 500,979 Cash, cash equivalents, and restricted cash at end of period $ 414,402 $ 549,962 Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets: Cash and cash equivalents $ 386,826 $ 512,364 Restricted cash included in other current assets 27,576 37,598 Cash, cash equivalents, and restricted cash at end of period $ 414,402 $ 549,962 Expand Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended March 31, 2025 2024 Reconciliation of GAAP gross profit to non-GAAP gross profit: GAAP gross profit $ 110,936 $ 92,623 GAAP gross margin 41.1 % 37.6 % Share-based compensation expense 1,718 1,555 Amortization of acquired intangibles 1,007 1,120 RDS restructuring — 2,696 Non-GAAP gross profit $ 113,661 $ 97,994 Non-GAAP gross margin 42.1 % 39.8 % Reconciliation of GAAP operating expenses to non-GAAP operating expenses: GAAP operating expenses $ 122,555 $ 114,470 GAAP operating expenses % to total revenues 45.4 % 46.5 % Share-based compensation expense (9,068 ) (7,086 ) Amortization of acquired intangibles (4,721 ) (4,840 ) Acquisition-related expenses (182 ) (246 ) RDS restructuring — (576 ) Legal and regulatory expenses (2,700 ) — Management severance costs (562 ) — Executives transition costs (968 ) — Non-GAAP operating expenses $ 104,354 $ 101,722 Non-GAAP operating expenses as a % of total revenues 38.7 % 41.3 % Reconciliation of GAAP loss from operations to non-GAAP income (loss) from operations: GAAP loss from operations $ (11,619 ) $ (21,847 ) GAAP operating loss % to total revenues (4.3 )% (8.9 )% Share-based compensation expense 10,786 8,641 Amortization of acquired intangibles 5,728 5,960 Acquisition-related expenses 182 246 RDS restructuring — 3,272 Legal and regulatory expenses 2,700 — Management severance costs 562 — Executives transition costs 968 — Non-GAAP income (loss) from operations $ 9,307 $ (3,728 ) Non-GAAP operating margin (non-GAAP operating income (loss) as a % of total revenues) 3.5 % (1.5 )% Expand Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended March 31, 2025 2024 Reconciliation of GAAP net loss to non-GAAP net income: GAAP net loss $ (7,023 ) $ (15,676 ) Share-based compensation expense 10,786 8,641 Amortization of acquired intangibles 5,728 5,960 Acquisition-related expenses 182 246 RDS restructuring — 3,272 Legal and regulatory expenses 2,700 — Management severance costs 562 — Executives transition costs 968 — Amortization of debt issuance costs 735 971 Tax effect of the adjustments above (a) (2,284 ) (2,194 ) Non-GAAP net income $ 12,354 $ 1,220 Reconciliation of GAAP net loss per share - diluted to non-GAAP net income per share - diluted: Shares - diluted GAAP 46,596 45,732 Shares - diluted non-GAAP 47,003 45,768 GAAP net loss per share - diluted $ (0.15 ) $ (0.34 ) Share-based compensation expense 0.23 0.19 Amortization of acquired intangibles 0.12 0.13 Acquisition-related expenses 0.00 0.01 RDS restructuring — 0.07 Legal and regulatory expenses 0.06 — Management severance costs 0.01 — Executives transition costs 0.02 — Amortization of debt issuance costs 0.02 0.02 Tax effect of the adjustments above (a) (0.05 ) (0.05 ) Non-GAAP net income per share - diluted $ 0.26 $ 0.03 Reconciliation of GAAP net loss to non-GAAP EBITDA (b): GAAP net loss $ (7,023 ) $ (15,676 ) Share-based compensation expense 10,786 8,641 Interest (income) and expense, net (2,805 ) (5,715 ) Depreciation and amortization expense 19,995 21,253 Acquisition-related expenses 182 246 RDS restructuring — 3,272 Legal and regulatory expenses 2,700 — Management severance costs 562 — Executives transition costs 968 — Amortization of debt issuance costs 735 971 Benefit from income taxes (2,507 ) (2,155 ) Non-GAAP EBITDA $ 23,593 $ 10,837 Non-GAAP EBITDA margin (non-GAAP EBITDA as a % of total revenues) 8.7 % 4.4 % Expand ______________________________________________ (a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2025 and 2024. (b) Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Expand
Yahoo
28-04-2025
- Business
- Yahoo
Unpacking Q4 Earnings: Omnicell (NASDAQ:OMCL) In The Context Of Other Healthcare Technology for Providers Stocks
Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Omnicell (NASDAQ:OMCL) and the best and worst performers in the healthcare technology for providers industry. The healthcare technology industry focuses on delivering software, data analytics, and workflow solutions to hospitals, clinics, and other care facilities. These companies enable providers to streamline operations, optimize patient outcomes, and transition to value-based care models. They boast subscription-based revenues or long-term contracts, providing financial stability and growth potential. However, they face challenges such as lengthy sales cycles, significant upfront investment in technology development, and reliance on providers' adoption of new tools, which can be hindered by budget constraints or resistance to change. Over the next few years, the sector is poised for growth as providers increasingly prioritize digital transformation and efficiency in response to rising healthcare costs and patient demand for seamless care. Tailwinds include the growing adoption of AI-driven tools for patient engagement and operational improvements, government incentives for digitization, and the expansion of telehealth and remote patient monitoring. However, headwinds such as tightening hospital budgets, cybersecurity threats, and the fragmented nature of healthcare systems could slow adoption. The 6 healthcare technology for providers stocks we track reported a slower Q4. As a group, revenues beat analysts' consensus estimates by 3.1% while next quarter's revenue guidance was 0.7% below. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 12.6% since the latest earnings results. Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency. Omnicell reported revenues of $306.9 million, up 18.6% year on year. This print exceeded analysts' expectations by 2.2%. Despite the top-line beat, it was still a slower quarter for the company with EBITDA guidance for next quarter missing analysts' expectations significantly and a miss of analysts' full-year EPS guidance estimates. 'We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year,' stated Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. The stock is down 31.9% since reporting and currently trades at $30.23. Read our full report on Omnicell here, it's free. Founded in 2005 to streamline the traditionally paper-heavy patient check-in process, Phreesia (NYSE:PHR) provides software solutions that automate patient intake, registration, and payment processes for healthcare organizations while improving patient engagement in their care. Phreesia reported revenues of $109.7 million, up 15.4% year on year, outperforming analysts' expectations by 0.7%. The business had a strong quarter with a solid beat of analysts' EPS estimates and full-year EBITDA guidance topping analysts' expectations. The market seems content with the results as the stock is up 1.4% since reporting. It currently trades at $24.21. Is now the time to buy Phreesia? Access our full analysis of the earnings results here, it's free. Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. Evolent Health reported revenues of $646.5 million, up 16.3% year on year, falling short of analysts' expectations by 0.7%. It was a softer quarter as it posted a significant miss of analysts' EPS estimates and EBITDA guidance for next quarter missing analysts' expectations significantly. Evolent Health delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 14.9% since the results and currently trades at $9.13. Read our full analysis of Evolent Health's results here. Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes. Premier reported revenues of $240.3 million, down 14.2% year on year. This number met analysts' expectations. Zooming out, it was a slower quarter as it produced a significant miss of analysts' EPS estimates. Premier had the slowest revenue growth among its peers. The stock is down 9.4% since reporting and currently trades at $20.30. Read our full, actionable report on Premier here, it's free. Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ:ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models. Astrana Health reported revenues of $665.2 million, up 88.4% year on year. This print topped analysts' expectations by 6.9%. More broadly, it was a mixed quarter as it also logged full-year revenue guidance beating analysts' expectations. Astrana Health delivered the fastest revenue growth and highest full-year guidance raise among its peers. The stock is down 15.8% since reporting and currently trades at $29.21. Read our full, actionable report on Astrana Health here, it's free. As a result of the Fed's rate hikes in 2022 and 2023, inflation has come down from frothy levels post-pandemic. The general rise in the price of goods and services is trending towards the Fed's 2% goal as of late, which is good news. The higher rates that fought inflation also didn't slow economic activity enough to catalyze a recession. So far, soft landing. This, combined with recent rate cuts (half a percent in September 2024 and a quarter percent in November 2024) have led to strong stock market performance in 2024. The icing on the cake for 2024 returns was Donald Trump's victory in the U.S. Presidential Election in early November, sending major indices to all-time highs in the week following the election. Still, debates around the health of the economy and the impact of potential tariffs and corporate tax cuts remain, leaving much uncertainty around 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
Yahoo
07-02-2025
- Business
- Yahoo
Omnicell Inc (OMCL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Total Revenue: $307 million, an increase of $24 million over the prior quarter and $48 million over Q4 2023. Product Revenue: $182 million, up $24 million from the previous quarter and $37 million from Q4 2023. Service Revenue: $125 million, an increase of $1 million over the previous quarter and $11 million over Q4 2023. Non-GAAP Gross Margin: 47.4%, an increase of 290 basis points from the prior quarter. GAAP Earnings Per Share (EPS): $0.34, compared to $0.19 in the prior quarter and a loss of $0.32 in Q4 2023. Non-GAAP EPS: $0.60, compared to $0.56 in the prior quarter and $0.33 in the same period last year. Non-GAAP EBITDA: $46 million, an increase of $8 million from the previous quarter and $23 million from the same period last year. Cash and Cash Equivalents: $369 million, down from $571 million as of September 30, 2024. Non-GAAP Free Cash Flow: $43 million for Q4 2024. Inventory: $89 million as of December 31, 2024, a decrease of $6 million from the prior quarter. Bookings for Full Year 2024: $923 million, exceeding guidance of $800 million to $875 million. Total Backlog: $1.201 billion as of December 31, 2024. Full Year 2024 Revenue: $1.112 billion, a decrease of $35 million or 3% from 2023. Full Year 2024 Non-GAAP EPS: $1.71, a decrease of $0.20 from 2023. Full Year 2024 Non-GAAP EBITDA: $136 million. Warning! GuruFocus has detected 5 Warning Signs with OMCL. Release Date: February 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Omnicell Inc (NASDAQ:OMCL) exceeded its bookings guidance for 2024, driven by strong demand for connected devices. The company returned to year-over-year revenue growth in Q4 2024, with total revenues reaching $307 million. Omnicell Inc (NASDAQ:OMCL) solidified its balance sheet by issuing new convertible senior notes and repurchasing a majority of the principal amount of previously outstanding notes. The XT Amplify program continues to gain traction, with significant customer wins and market share gains. Annual recurring revenue (ARR) is expected to grow, contributing significantly to overall revenue, with specialty pharmacy services as a key driver. Despite strong bookings, Omnicell Inc (NASDAQ:OMCL) anticipates product bookings to be flat to modestly down in 2025 compared to 2024. The company faces a $0.20 headwind to non-GAAP earnings per share in 2025 due to reduced interest income from repurchasing convertible senior notes. Cash and cash equivalents decreased significantly from $571 million to $369 million by the end of Q4 2024. Omnicell Inc (NASDAQ:OMCL) is concluding the XT replacement cycle, which may impact future bookings and revenue growth. The company is navigating potential tariff risks and cost of goods challenges, although it has strategies in place to mitigate these impacts. Q: Can you expand on the end market demand and how it translates into budget growth? A: Randall Lipps, CEO, explained that hospital financial conditions have improved, contributing to strong bookings in the fourth quarter. This positions Omnicell well for 2025, with expectations for continued growth into 2026. The improved financial position of customers makes decision-making easier, and the excitement around the XT Amplify program facilitates investment now rather than later. Q: How should we think about the trajectory of gross margin and operating expense growth in 2025? A: Nchacha Etta, CFO, noted that gross margins improved in 2024 and are expected to continue improving in 2025. This will be driven by managing expenses, favorable product and customer mix, and operational improvements. The focus remains on improving overall profitability through fiscal discipline. Q: What contributed to the upside in bookings in 2024? A: Nchacha Etta, CFO, highlighted significant demand for connected devices and additional bookings from XT upgrades, including market share gains. The XTExtend program also contributed to improved bookings performance. Q: How does the new administration's focus on technology innovation impact Omnicell's business? A: Randall Lipps, CEO, stated that the administration's focus on efficiency and safety aligns with Omnicell's core strengths. The company is well-positioned to leverage its innovation in making customers more efficient and safe, which should drive better returns and outcomes. Q: What is the outlook for the XT Amplify and XTExtend pipelines? A: Nchacha Etta, CFO, mentioned that the adoption of XT Amplify and XTExtend follows a traditional bell curve. Hospitals are moving back into capital equipment markets, which could accelerate adoption. The company is optimistic about continuing momentum into 2025 and beyond. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
